Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 13/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18980368 | 1.00 | TLR8 (0.40) | TLR8PDE3BPDE3ARBP4PPARG | |
| SCHEMBL29722378 | 1.00 | TLR8 (0.40) | TLR8PDE3BPDE3ARBP4PPARG | |
| SCHEMBL18980370 | 1.00 | TLR8 (0.40) | TLR8PDE3BPDE3ARBP4PPARG | |
| SCHEMBL18980682 | 0.86 | TLR8 (0.53) | TLR8RBP4PPARGCYP2C19HCRTR1 | |
| SCHEMBL29722299 | 0.86 | TLR8 (0.53) | TLR8RBP4PPARGCYP2C19HCRTR1 | |
| SCHEMBL18980683 | 0.86 | TLR8 (0.53) | TLR8RBP4PPARGCYP2C19HCRTR1 | |
| SCHEMBL18980680 | 0.86 | TLR8 (0.53) | TLR8RBP4PPARGCYP2C19HCRTR1 | |
| SCHEMBL18980205 | 0.85 | PIM2 (0.42) | TLR8NOTUM | |
| SCHEMBL30571035 | 0.85 | PIM2 (0.42) | TLR8NOTUM | |
| Hydrochloric Acid SCHEMBL23855279 | 0.84 | PIM2 (0.42) | TLR8NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2023-04-18 | — | — | US | disclosed |
| CN-108699032-B | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-113603675-A | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-03-26 | — | — | US | disclosed |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-01-28 | — | — | US | disclosed |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 2196/4885PDE3A 1920/4885 |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 2196/4885PDE3A 1920/4885 |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 2196/4885PDE3A 1920/4885 |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 1893/4885PDE3A 1672/4885 |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 2196/4885PDE3A 1920/4885 |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 2196/4885PDE3A 1920/4885 |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 2196/4885PDE3A 1920/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 2196/4885PDE3A 1920/4885 |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 1843/4885PDE3A 1752/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 1843/4885PDE3A 1752/4885 |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | TLR8 2/4885PDE3B 2196/4885PDE3A 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.